The comparison of treatments with and without azithromycin in irritable bowel syndrome with diarrhea-predominant in gastrointestinal Clinic of Al-Zahra Hospital, Isfahan, Iran


1 Department of Infectious Disease, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Internal Medicine, School of Medicine, Islamic University, Najafabad Branch, Isfahan, Iran

3 Integrative Functional Gastroenterology Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran


Background: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder. Recent studies suggest the importance of gut flora in the pathophysiology of it. Therefore, antibiotics have demonstrated a substantial benefit to reduce gut flora. Having few side effects, and applying one-dose per day, we studied the effect of azithromycin to treat IBS.
Materials and Methods: One hundred and twenty-six patients enrolled a randomized, double-blind, placebo-controlled study. The treatment group received azithromycin in addition to common treatment. Patients were followed for 12 weeks. Patients completed daily diaries documenting their symptoms.
Results: One hundred and thirteen patients completed the study. The onset of relief occurred significantly sooner, and duration of relief was significantly longer in azithromycin group. Movement, abdominal pain, bloating, and gas were significantly better in azithromycin group. Monthly results showed superior relief in bloating, gas, overall symptom, and overall bloating during 3 months. Significantly more patients in azithromycin group felt relief in bloating and gas and had greater consistency relief in almost all weeks.
Conclusion: In our study, azithromycin significantly relieved most symptoms, such as abdominal pain, bloating, and gas. Overall symptom and overall bloating were relieved significantly in more patients in the intervention group in all weeks.


Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001;161:1733-40.  Back to cited text no. 1
Viera AJ, Shaughnessy J. Management of irritable bowel syndrome – Cover article. Pract Ther 2002;1867-74.  Back to cited text no. 2
Keshteli AH, Dehestani B, Daghaghzadeh H, Adibi P. Epidemiological features of irritable bowel syndrome and its subtypes among Iranian adults. Ann Gastroenterol 2015;28:253-8.  Back to cited text no. 3
Posserud I, Strid H, Störsrud S, Törnblom H, Svensson U, Tack J, et al. Symptom pattern following a meal challenge test in patients with irritable bowel syndrome and healthy controls. United European Gastroenterol J 2013;1:358-67.  Back to cited text no. 4
Abbasi MH, Zahedi M, Darvish Moghadam S, Shafieipour S, HayatBakhsh Abbasi M. Small bowel bacterial overgrowth in patients with irritable bowel syndrome: The first study in Iran. Middle East J Dig Dis 2015;7:36-40.  Back to cited text no. 5
Basseri RJ, Weitsman S, Barlow GM, Pimentel M. Antibiotics for the treatment of irritable bowel syndrome. Gastroenterol Hepatol (N Y) 2011;7:455-93.  Back to cited text no. 6
Ford AC. Management of irritable bowel syndrome. Minerva Gastroenterol Dietol 2009;55:273-87.  Back to cited text no. 7
Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32.  Back to cited text no. 8
Jahangiri P, Jazi MS, Keshteli AH, Sadeghpour S, Amini E, Adibi P. Irritable bowel syndrome in Iran: SEPAHAN systematic review no 1. Int J Prev Med 2012;3 Suppl 1:S1-9.  Back to cited text no. 9
Garsed K, Chernova J, Hastings M, Lam C, Marciani L, Singh G, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 2014;63:1617-25.  Back to cited text no. 10
Olden KW. Targeted therapies for diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol 2012;5:69-100.  Back to cited text no. 11
Barbuti R, Navarro-Rodriguez T, de Moraes-Filho J. Functional diseases of the digestive system: Irritable bowel syndrome. Intern Med 2014;4:2.  Back to cited text no. 12
Ringel Y, Williams RE, Kalilani L, Cook SF. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2009;7:68-72.  Back to cited text no. 13
Mayer EA. Clinical practice. Irritable bowel syndrome. N Engl J Med 2008;358:1692-9.  Back to cited text no. 14
Deiana S, Gabbani T, Bagnoli S, Annese V. Emerging drug for diarrhea predominant irritable bowel syndrome. Expert Opin Emerg Drugs 2015;20:247-61.  Back to cited text no. 15
Lee HR, Pimentel M. Bacteria and irritable bowel syndrome: The evidence for small intestinal bacterial overgrowth. Curr Gastroenterol Rep 2006;8:305-11.  Back to cited text no. 16
Vanner S. The small intestinal bacterial overgrowth. Irritable bowel syndrome hypothesis: Implications for treatment. Gut 2008;57:1315-21.  Back to cited text no. 17
Posserud I, Stotzer PO, Björnsson ES, Abrahamsson H, Simrén M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007;56:802-8.  Back to cited text no. 18
Saadi M, McCallum RW. Rifaximin in irritable bowel syndrome: Rationale, evidence and clinical use. Ther Adv Chronic Dis 2013;4:71-5.  Back to cited text no. 19
Ghoshal UC, Srivastava D. Irritable bowel syndrome and small intestinal bacterial overgrowth: Meaningful association or unnecessary hype. World J Gastroenterol 2014;20:2482-91.  Back to cited text no. 20
Chang FY. Irritable bowel syndrome: The evolution of multi-dimensional looking and multidisciplinary treatments. World J Gastroenterol 2014;20:2499-514.  Back to cited text no. 21
Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: A systematic review and meta-analysis. Am J Gastroenterol 2012;107:28-35.  Back to cited text no. 22
Camilleri M. Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome. Expert Opin Pharmacother 2013;14:1151-60.  Back to cited text no. 23
Lembo A, Zakko SF, Ferreira NL, Ringel Y, Bortey E, Courtney K, et al. T1390 rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: Short term treatment leading to long term sustained response. Gastroenterology 2008;134:A-545.  Back to cited text no. 24
Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial. Ann Intern Med 2006;145:557-63.  Back to cited text no. 25
Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003;98:412-9.  Back to cited text no. 26
Parodi A, Dulbecco P, Savarino E, Giannini EG, Bodini G, Corbo M, et al. Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. J Clin Gastroenterol 2009;43:962-6.  Back to cited text no. 27
Koo HL, Sabounchi S, Huang DB, DuPont HL. Rifaximin therapy of irritable bowel syndrome. Clin Med Insights Gastroenterol 2012;5:31-41.  Back to cited text no. 28